Science-Focused Conference on Cannabis Therapeutics Offers Plenty for MMJ Professionals
The upcoming Seventh National Clinical Conference on Cannabis Therapeutics in Arizona might sound a bit dry to the average professional in the medical marijuana industry.
Just take a look at the lineup of science-focused sessions, which feature titles such as “Overview of the Endocannabinoid System,” “Empirical Rationales for the Possibility of Cannabis Therapeutics in Post Traumatic Stress,” and “Phytocannabinoids in the Treatment of Breast Cancer and Glioma Cell Cancer.” Speakers include doctors, researchers, nonprofit heads and executives of health care companies from across the United States and as far away as Israel.
But don’t let the health focus deter you from attending: There’s plenty of benefits for dispensary owners, vendors and other involved more in the business side of medical cannabis.
For starters, the conference will provide a solid overview of how cannabis is used as medicine for many different ailments, giving MMJ professionals a better understanding of the industry – and the product it revolves around – in general. As Robert Kane – who publishes an investment-focused newsletter about medical marijuana and provides consulting to cannabis companies – puts it: “How can you be part of the medical industry if you don’t have an understanding of the medicine?”
The conference also offers a great networking and business opportunity for entrepreneurs looking to get into the industry and current players, as many movers and shakers in medical cannabis will be on hand (an estimated 350 people are expected to attend). Fellow MMJ lawyers, doctors who write cannabis prescriptions, investors, patients and advocates are expected to be in the crowd.
There will also be vendor booths for organizations and companies to spread the word about their services and products.
The conference will held from April 26 to 28 at the Loews Ventana Canyon in Tuscon, Arizona. Registration costs $315 for professionals and $215 for the general public. This year’s focus is on the emerging science of the endogenous cannabinoid system (ECS), with the aim of helpping clinicians “understand how and why cannabis is safe and effective for such a wide variety of health problems.”
Sponsors of the event include Patients Out of Time, the University of California – San Francisco School of Medicine and the University of Arizona College of Nursing.
For more information or to register, visit this link – (note: the site was not loading correctly at the time of this posting).
Florida is having a hard time figuring out rules for its CBD industry. The state [click to continue...]
Dispensaries in Maine sold an estimated $16.2 million worth of medical cannabis last year, while [click to continue...]
Oregon could keep medical marijuana completely separate from recreational cannabis when retail sales begin next [click to continue...]
Missouri has joined the growing number of states legalizing CBD-based medicines. The state awarded cultivation [click to continue...]
Dispensaries and retail cannabis stores in Colorado sold nearly 150,000 pounds of marijuana flower last [click to continue...]
Recreational marijuana has dominated headlines out of Washington DC this week, as the use, possession [click to continue...]
A company that got turned down for one of the Illinois’ 21 medical marijuana cultivation [click to continue...]
A financial services firm that plans to serve the cannabis industry has secured $2 million [click to continue...]
Alaska marijuana entrepreneurs who want to specialize in infused products or extracts will have to [click to continue...]
With private marijuana use on track to become legal in Washington DC on Thursday barring [click to continue...]
Oregon is facing an interesting question tied to its medical marijuana law: Should evicted cannabis [click to continue...]
Institutional investors will put money into cannabis stocks this year, though many publicly traded MJ [click to continue...]
Alaska Gov. Bill Walker has sent a bill to state lawmakers calling for the establishment [click to continue...]
Canadian stock regulators have a word of warning for those investing in MMJ companies north [click to continue...]